Proceeds will fund expansion of the company’s ongoing Phase 1 / 2 clinical trial and development programs CHICAGO and FORT WORTH, Texas, May 16, 2019-- Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the financing to expand the company’s ongoing Phase 1 / 2 clinical trial and fund development programs.